Articles tagged with Breast Cancer Cells
Researchers found that tiny lipid bubbles packed with melatonin can make tamoxifen stronger and help kill cancer cells. The treatment reduces the need for higher doses of tamoxifen, minimizing severe side effects.
Researchers discovered an enzyme that slows cell growth in breast cancer cells by increasing cyclic GMP production. Histone deacetylase inhibitors also relax blood vessels, suggesting potential therapeutic applications for erectile dysfunction and other diseases.
Scientists have built a model to investigate the metastasis of cancer by examining the metabolism of breast epithelial cells. The study shows how the metabolic signposts of cancer cell growth can be predicted based on EGFR signaling genes.
Researchers have discovered a new protein compound that binds to two HER2 receptors simultaneously, preventing growth signals and killing cancer cells. This innovative solution shows great promise in treating invasive breast cancer more effectively.
A new compound called Fasnall has been discovered to impede the proliferation of breast cancer cells in mice. By inhibiting the normal activity of fatty acid synthase, an enzyme that regulates cell growth and proliferation, Fasnall also contributed to the death of existing cancer cells.
A multi-institutional team has completed the first large-scale proteogenomic study of breast cancer, linking DNA mutations to protein signaling and identifying genes that drive cancer. The study highlights the power of integrating genomic and proteomic data to yield a more complete picture of cancer biology.
Researchers have identified a molecular key that allows breast cancer cells to invade bone marrow in mice, where they may be protected from chemotherapy or hormonal therapies. The study found ways to outmaneuver this tactic by preventing cancer cells from entering the bone marrow and flushing them into the bloodstream for destruction.
Researchers at Boston University School of Medicine found similarities in genetic and epigenetic alterations between breast and ovarian cancers. The study suggests that better understanding of these changes may lead to more effective chemotherapeutics and strategies to circumvent drug resistance.
A new study using mice and lab-grown human cells shows a triple-drug cocktail can shrink triple-negative breast cancers by killing off cancer cells and halting new tumor growth. The combination treatment, EAD therapy, reduced the size of tumors in mice and decreased tumor growth in spheres grown from patients' metastatic cells.
A recent study by Johns Hopkins Kimmel Cancer Center scientists reveals that the HOXA5 protein plays a crucial role in maintaining normal breast cells' traits, such as adhesion and cell plasticity. The loss of HOXA5 leads to increased tumor aggressiveness and poorer outcomes for patients.
Breast cancer tumor-initiating cells use mTOR signaling to recruit myeloid-derived suppressor cells (MDSCs), which are involved in suppressing the body's response against tumors. This interaction helps researchers understand the events leading to tumor growth and metastasis, identifying potential therapeutic targets.
Researchers have identified a snitch that reveals cancer cells to the immune system by producing interferon, activating macrophages and T cells to kill cancer cells. MUS81 enzyme plays a crucial role in this process, triggering an immune response in cancer cells.
Researchers have developed a nanoblade that can slice through cell membranes to insert mitochondria, with successful transfer rates of up to 2%. This technology holds promise for studying mitochondrial diseases and advancing fields like infectious diseases research.
Scientists at Scripps Research Institute designed a drug candidate that targets cancer-causing RNA, eliminating side effects and reducing tumor growth. The study demonstrates a clear breakthrough in precision medicine, using computational approaches to develop designer compounds.
Researchers have discovered that a combination of 5-azacytidine and the HDAC inhibitor butyrate reduces the number of cancer stem cells in breast cancer patients. This targeted approach may improve survival rates and provide a new treatment option for breast cancer.
A recent study at The Hormel Institute has uncovered a new molecular mechanism that detects missegregated chromosomes and prevents the formation of tumors. This discovery provides insight into the regulation of chromosome segregation and its role in cancer development.
Cancer cells' ability to slide past obstacles and travel out of primary tumors is enabled by abnormal protein fiber scaffolding and the agility of cancer cells themselves. The researchers developed a model environment that mimics protein fibers, allowing them to observe and quantify the behavior of breast cancer cells.
Breast cancer cells challenged with a small-molecule inhibitor targeting specific invasive properties switch to an alternative mode-of-action, rendering them even more aggressive. The results suggest that inhibiting one pathway may not block all aggressiveness in breast cancer cells.
Researchers found that breast cancer cells spread by sliding around other cells blocking their escape route out of the original tumor. The study identified molecular pathways that regulate cell-sliding behavior and showed that increased levels of E-cadherin can diminish this behavior.
Researchers at the Walter and Eliza Hall Institute have uncovered a crucial mechanism behind rich milk production in lactation. Breast cells develop two nuclei during pregnancy, allowing for optimal milk production, which is essential for newborn survival. This discovery sheds new light on the intricate processes involved in lactation.
Researchers found that breast cancer stem cells secrete molecules that allow neighboring cells to detach and metastasize. The hedgehog signaling pathway plays a crucial role in this process, suggesting that targeting it could reduce metastatic potential.
Researchers developed a method to isolate circulating tumor cells from blood samples using gas microbubbles. The technique successfully isolated up to 80% of cancer cells in some cases, offering a rapid and inexpensive way to analyze these rare and fragile cells.
Researchers at Cornell University and Bar-Ilan University discovered a novel mechanism for mutation in primates triggered by the APOBEC family of virus-fighting enzymes. These enzymes can rapidly generate large changes in genes through 'friendly fire' events, which may have been passed on to subsequent generations.
A team of scientists has turned off a key protein that fuels the growth of aggressive breast cancer cells, making them more vulnerable to chemotherapy. The study reveals a pivotal catalyst in the development of triple-negative breast cancer and paves the way for new therapies.
A new hybrid molecule has been developed by NYU Tandon researchers that can carry and deliver anti-cancer drugs to malignant cells. The protein-gold nanoparticle composite enhances small-molecule loading, sustained release, and increased uptake in breast cancer cells.
Researchers found that cancer stem cells multiply through the same mechanism used by embryonic stem cells, encouraged by low oxygen levels. The discovery could offer a path to targeting cancer stem cells and reducing their threat in human cancer.
Researchers at Imperial College London found that a protein called MARK4 enables cancer cells to break free and move around the body. A silencer molecule called miR-515-5p helps silence the gene that produces MARK4, preventing cancer cells from spreading.
Scientists have identified a new gene, GT198, that causes breast cancer and can be used to diagnose the disease early. The gene is normally regulated by estrogen but becomes mutated when it causes rapid growth of cancer cells.
Researchers developed an antibody against KCNK9, a cellular gateway that suppresses lung tumor cell growth and breast cancer metastasis. The antibody reduced tumor growth by up to 70% and slowed metastases in mice.
The ROBO1 signaling pathway enhances cellular contractility and adhesion in response to stiff environments, allowing cells to retain shape and position. This upregulation of ROBO1 may prevent cell invasion and delay tumor progression.
A University of Houston researcher has discovered a link between alcohol and breast cancer, finding that alcohol enhances the actions of estrogen in driving breast cancer cell growth. The study also found that alcohol weakens the effectiveness of a cancer drug called Tamoxifen.
Researchers found that radiation treatment killed 95% of breast cancer cells when delivered during a peak in p53 production, but only 20% when applied during an oscillatory phase. The study suggests that timing may be crucial in understanding the effectiveness of anticancer treatments.
Researchers found that inhibiting calcium transfer to mitochondria selectively kills cancer cells by inducing bioenergetic crisis and autophagy. Providing metabolic substrates rescues the lethal effect, suggesting that cell death is caused by compromised bioenergetics.
Researchers at the Niels Bohr Institute have developed a new cancer treatment that uses nanoparticles to transport cytotoxin directly to cancer cells via the bloodstream. The treatment has been shown to be effective in targeting and destroying cancer cells while leaving healthy cells unaffected.
Whitehead Institute researchers develop hydrogel scaffolds that support human mammary tissue growth from patient-derived cells, providing insights into normal breast development and cancer progression. The scaffold responds to hormones and allows for the study of gene perturbations.
A study of 120,000 women found five genetic variants affecting breast cancer risk, which alter how cells respond to oestrogen. The variants are associated with changes in the expression of genes involved in oestrogen regulation, potentially leading to new breast cancer preventions.
Researchers have found a way to activate natural killer cells, which hunt and destroy cancer cells, by targeting the 'switch' protein ID2. This discovery could lead to new treatments for breast, colon, and melanoma cancers.
Researchers developed a new screening protocol to detect human polyomaviruses in tumor samples, but found no association with various types of cancer. The technique will aid in studying diseases linked to polyomaviruses, such as Merkel cell carcinoma caused by Merkel cell polyomavirus.
Researchers have discovered that synthetic plant hormones MEB55 and ST362 can effectively cause DNA damage and turn off a major DNA repair mechanism, making them promising agents for treating human prostate cancer. When combined with PARP inhibitors, these agents halt both DNA repair pathways, leading to the death of cancer cells.
Researchers identified EPHA2 as a key regulator of breast cancer cell spread from blood vessels. The study sheds light on how tumour cells interact with blood vessel walls and exchange information to control their movement.
Scientists have identified a piece of non-coding RNA that stops cells from turning cancerous, regulating cell growth and metastasis. The discovery could lead to new treatments for cancer.
A recent study found that the presence of Epidermal Growth Factor (EGF) promotes the motility of elongated mesenchymal tumour cells in breast cancer cells, which migrate along collagen fibres. This increased persistence and moderate speed suggests that EGF contributes to modulating the mobility of tumour cells.
Researchers found epigenetic alterations in normal breast tissue adjacent to cancer, marking susceptible precursor cells. These changes were associated with poorer prognosis and decreased survivorship from the disease. The study aims to decode how breast cancer develops and understand risk factors.
The study confirms the importance of sugar to cancer survival and provides essential new information for developing PI3K inhibitor drugs. The discovery creates a previously unidentified link between a cancer cell's form and shape and its metabolic capabilities.
Berkeley Lab researchers find XPG plays a critical role in maintaining genome stability, raising the possibility that it prevents breast and ovarian cancers. The protein interacts with BRCA1 and BRCA2 to carry out homologous recombination repair.
University of Iowa researchers track cancerous human breast tissue cells' motion and accretion into tumors, discovering that only five percent of cancerous cells are needed to form a tumor. The team finds that cancer cells actively recruit healthy cells by extending cables to grab their neighbors, forming a larger mass.
A Northwestern University study uses fruit fly genetics to understand how normal cells switch to specialized states and how this process might go wrong in cancer. Researchers found that a protein called Yan fluctuates wildly during this transition, suggesting a critical role in the development of cancer cells.
Scientists have identified WASF3 as a solid target for reducing cancer's ability to spread. By interrupting its relationship with CYFIP1, they were able to suppress the ability of invasive human breast and prostate cancer cells to metastasize. This finding has potential applicability to other common cancers.
A recent study suggests new potential drug targets and combinations for treating breast cancer, including signaling proteins and proteins that regulate cell growth pathways. The research identifies candidate genes essential to cancer cell survival and validates a gene as a target for further study.
A multi-institutional international study has revealed new information about the interaction between long non-coding RNAs and HIF-1 signaling pathways in triple-negative breast cancer. The study identifies four previously unknown phosphorylation sites, which predict a worse outcome for TNBC patients, suggesting that these sites could s...
Researchers found that auranofin reduces the survival rates of ovarian cancer cells with depleted BRCA1 levels, increasing their sensitivity to the drug. This suggests auranofin's potential as a clinical treatment for ovarian cancers with BRCA1 deficiency.
Researchers at Boston University School of Medicine identified a metastasis suppressor gene called serum deprivation response (SDPR), which plays a role in breast cancer progression. Over-expression of SDPR reduces the incidence of metastatic disease in models of aggressive, metastatic breast cancer cells.
Researchers have identified a specific weakness in the immune system of patients with HER2-positive breast cancer, which may be corrected with a HER2-targeted vaccine. T cells from patients with recurrent cancer showed weaker response to the HER2 receptor protein compared to those without recurrence.
The new oral drug Palbociclib has shown promise in combating various types of cancer beyond breast cancer, including lymphoma, sarcoma, and teratoma. Early trials have demonstrated its effectiveness in slowing tumor growth and improving survival rates in patients with these conditions.
A machine learning algorithm identified 18 potential combinations of existing and previously unknown compounds that can work together as antifungal agents, confirming their potential for drug development. The study also found some compound combinations were harmless when applied to human cell lines.
Cancer cells use nanoscale bridges to communicate with healthy cells, leading to metastasis. Researchers discovered that disrupting these bridges can prevent cancer cell spread using pharmacological agents.
Researchers at Berkeley Lab have created a clinically relevant mouse model of human breast cancer, bearing resemblance to the most prevalent form of breast cancer. The model, '184AA3,' will enable testing of therapies for aggressive ER+ breast cancers and studying the biology and etiology of luminal cancers.
Researchers discovered that bone's dynamic process of building and breaking down can send signals to cancer cells to stay asleep or wake. The study showed that cancer cells are usually kept asleep by association with bone-lining cells, but can be woken by activating osteoclasts.
Scientists discovered a 'master switch' in cancer cells that allows them to survive stress conditions by overriding the normal stress response. The Brf2 protein acts as a sensor and regulates gene activity, enabling cancer cells to thrive under stress.
Researchers at Thomas Jefferson University discovered that both strands of a tiny microRNA are active in suppressing genes in triple negative breast cancer cells. This breakthrough enables the design of specific blockers of one microRNA strand without imitating the opposite strand, opening a pathway to new treatments.